Market Research Logo

Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth

Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth

Summary


Epilepsy is a chronic medical disorder or condition in which the brain is overactive, sending too many signals, usually resulting in unpredictable, unprovoked recurrent seizures that affect a variety of mental and physical functions. Epilepsy is the fourth most common neurological disorder, affecting more than 65 million individuals worldwide. Epilepsy can start at any age, but is most commonly diagnosed in people under 20 and people over 65. This is because some causes are more common in young people (such as difficulties at birth, childhood infections or accidents) and in older people (such as strokes that lead to epilepsy).

Epilepsy treatment has historically been dominated by gamma aminobutyric acid (GABA) modulators and sodium channel blockers, leaving a wide unmet need intact in a sizeable section of patients who do not respond to the existing treatment options. Historically there is a lack of potent disease modifying or curative drugs in the epilepsy therapeutic space. The dominant older generation AEDs had poor safety and tolerability profiles. Second generation AEDs with newer mechanisms of action; signaled a shift in this trend in the last decade with improved tolerability and efficacy.

Epilepsy market in the five major geographies in the Asia-Pacific (APAC) region (Australia, China, India, Japan and South Korea) is expected to increase at a compound annual growth rate (CAGR) of 3.5% to reach $1.75 billion in 2024. The value of the market is expected to grow more rapidly in India and China compared with the more developed markets, Japan and Australia. With a high prevalence, these two regions have large treatment populations, which are expected to grow further due to better healthcare access and improvements in treatment gaps.

The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch during the forecast period. These drugs are under development with novel mechanisms of actions that are not conventional in the epilepsy market and are expected to provide greater efficacy and safety than previous AEDs. The launch and uptake of these new pipeline therapies with better efficacy are expected to drive APAC market growth.

Scope

  • The APAC epilepsy market will be valued at $1.7 billion in 2024, growing from $1.4 billion in 2017 at a CAGR of 3.5%.
  • How will the approval of Cenobamate for treatment-resistant epilepsy affect the competitive landscape, with no therapy currently available to address this patient subset?
  • The epilepsy market is crowded with cheap, generic, “me-too” drugs. What are the main barriers a new therapy faces when entering the epilepsy market?
  • The pipeline for epilepsy therapy is not diverse in terms of molecule type and molecular targets.
  • How have the late-stage therapies performed in clinical trials?
  • The level of unmet need in the epilepsy market is high. Will the pipeline drugs fulfill these unmet needs?
  • The market forecasts indicate that India and China will contribute the most to the APAC market.
  • How will the annual cost of therapy and market size vary between the five assessed APAC markets?
  • How will the growing population affect the market?
  • How will the various drivers and barriers influence the market over the forecast period?
  • Licensing deals are the most common form of strategic alliance in epilepsy, with total deal values ranging from under $0.1m to over $820m.
  • How do deal frequency and value compare between target families and molecule types?
Reasons to buy

This report will enable you to:
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the epilepsy market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the epilepsy pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict epilepsy market growth in the five assessed APAC markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the epilepsy deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
      • Table Figure 1: Epilepsy Therapeutics Market, Patient Distribution in APAC
    • Epidemiology
    • Disease Classification
      • Table Epilepsy Therapeutics, Global, Types of Seizures, 2017
    • Symptoms
    • Etiology and Pathophysiology
      • Etiology
        • Table Causes of Epilepsy According to Age
      • Pathophysiology
        • Table Figure 2: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
    • Diagnosis
      • Table Figure 3: Algorithm for investigation of patient presenting with seizure
      • Biomarkers
        • Table Examples of Biomarkers Needed in Different Epilepsy Indications
    • Prognosis
    • Treatment Guidelines and Options
      • Treatment Options
        • Table AED Options by Seizure Type
        • Table Figure 4: Algorithm for Choice of AED for New-Onset Epilepsy Patients
        • Table Figure 5: Treatment Algorithm for Status Epilepticus in Australia
  • Marketed Products
    • Overview
      • Aptiom/Zebinix (Eslicarbazepine acetate) - BIAL-Portela
      • Banzel/Inovelon (Rufinamide) - Novartis
      • Briviact (Brivaracetam) - UCB
      • Fycompa (perampanel) - Eisai
      • Keppra (levetiracetam) - UCB
      • Lyrica (pregabalin) - Pfizer
      • Vimpat (lacosamide) - UCB
      • Lamictal (lamotrigine) - GSK
      • Epidiolex (Cannabidiol) - GW Pharmaceuticals
      • Older Generation AEDs
    • Comparative Efficacy and Safety of Marketed Product
      • Table Figure 6: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
  • Pipeline Analysis
    • Overview
    • Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
      • Table Figure 7: Pipeline for Epilepsy Therapeutics, Global, 2018
    • Pipeline Distribution by Molecular Target
      • Table Figure 8: Pipeline for Epilepsy Therapeutics by Molecular Target, Global, 2018
    • Promising Pipeline Candidates
      • Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) - Zogenix
        • Table Figure 9: Epilepsy Therapeutics Market, APAC, ZX008 Forecast ($m), 2020-2024
      • Cenobamate (YKP3089) - SK Biopharmaceuticals
        • Table Figure 10: Epilepsy Therapeutics Market, APAC, Cenobamate Forecast ($m), 2020-2024
    • Comparative Efficacy and Safety of Pipeline Products
      • Table Figure 11: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 12: Epilepsy Therapeutics Market, Competitor Matrix for Epilepsy Marketed and Pipeline Products
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 13: Epilepsy Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017
      • Failure Rate by Phase and Molecule Type
      • Failure Rate by Phase and Molecular Target
        • Table Figure 14: Epilepsy Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007- 2017
    • Clinical Trial Size
      • Patient Enrollment per Product by Molecule Type and Stage of Development
        • Table Figure 15: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017
      • Patient Enrollment per Product by Molecular Target and Stage of Development
        • Table Figure 16: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017
      • Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
        • Table Figure 17: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017
      • Patient Enrollment per Trial by Molecular Target and Stage of Development
        • Table Figure 18: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017
    • Clinical Trial Duration
      • Clinical Trial Duration by Molecule Type
        • Table Figure 19: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007- 2017
      • Clinical Trial Duration by Molecular Target
        • Table Figure 20: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007- 2017
    • Competitive Clinical Trials Metrics Analysis
      • Table Figure 21: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 22: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-scenario Forecast
    • Geographical Markets
    • Asia-Pacific Market
      • Table Figure 23: Epilepsy Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2017-2024
      • Table Figure 24: Epilepsy Therapeutics Market, APAC, Market Size ($m), 2017-2024
    • India
      • Treatment Usage Patterns
        • Table Figure 25: Epilepsy Therapeutics Market, India, Treatment Patterns (million), 2017-2024
      • Annual Cost of Therapy
        • Table Figure 26: Epilepsy Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024
      • Market Size
        • Table Figure 27: Epilepsy Therapeutics Market, India, Market Size ($m), 2017-2024
    • China
      • Treatment Usage Patterns
        • Table Figure 28: Epilepsy Therapeutics Market, China, Treatment Patterns (million), 2017-2024
      • Annual Cost of Therapy
        • Table Figure 29: Epilepsy Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024
      • Market Size
        • Table Figure 30: Epilepsy Therapeutics Market, China, Market Size ($m), 2017-2024
    • Australia
      • Treatment Usage Patterns
        • Table Figure 31: Epilepsy Therapeutics Market, Australia, Treatment Patterns (`000), 2017-2024
      • Annual Cost of Therapy
        • Table Figure 32: Epilepsy Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024
      • Market Size
        • Table Figure 33: Epilepsy Therapeutics Market, Australia, Market Size ($m), 2017-2024
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 34: Epilepsy Therapeutics Market, South Korea, Treatment Patterns (`000), 2017-2024
      • Annual Cost of Therapy
        • Table Figure 35: Epilepsy Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
      • Market Size
        • Table Figure 36: Epilepsy Therapeutics Market, South Korea, Market Size ($m), 2017-2024
    • Japan
      • Treatment Usage Patterns
        • Table Figure 37: Epilepsy Therapeutics Market, Japan, Treatment Patterns (000), 2017-2024
      • Annual Cost of Therapy
        • Table Figure 38: Epilepsy Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024
      • Market Size
        • Table Figure 39: Epilepsy Therapeutics Market, Japan, Market Size ($m), 2017-2024
  • Drivers and Barriers
    • Drivers
      • Improved Economy and Affordability Boost the Market
      • Promising Pipeline Products that Target Unmet Needs for Epilepsy
      • Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment
    • Barriers
      • Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates
      • Impending Patent Cliffs and Generic Erosion
      • Lack of Strong Patent Protection or Intellectual Property Rights.
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
        • Table Figure 40: Epilepsy Therapeutics Market, Global, Licensing Deals By Region And Value, 2007-2018
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 41: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 42: Epilepsy Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
        • Table Figure 43: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018
        • Table Figure 44: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018
    • Key Licensing Deals
      • Table Epilepsy Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2018
    • Co-development Deals
      • Deals by Region and Value
        • Table Figure 45: Epilepsy Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 46: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Codevelopment Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2008-2018
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 47: Epilepsy Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018
        • Table Figure 48: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2018
        • Table Figure 49: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007- 2018
    • Key Co-development Deals
      • Table Epilepsy Therapeutics Market, Global, Co-development Deals, 2007-2018
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
      • Preclinical
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
      • IND/CTA-filed
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018
      • Phase I
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
      • Phase II
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
      • Phase III
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
      • Pre-registration
        • Table Epilepsy Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018
    • Summary of Multi-scenario Market Forecasts to 2024
      • Asia-Pacific
        • Table Epilepsy Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024
      • India
        • Table Epilepsy Therapeutics Market, India, Market Forecast, 2017-2024
      • China
        • Table Epilepsy Therapeutics Market, China, Market Forecast, 2017-2024
      • Australia
        • Table Epilepsy Therapeutics Market, Australia, Market Forecast, 2017-2024
      • South Korea
        • Table Epilepsy Therapeutics Market, South Korea, Market Forecast, 2017-2024
      • Japan
        • Table Epilepsy Therapeutics Market, Japan, Market Forecast, 2017-2024
    • Bibliography
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report